<DOC>
	<DOCNO>NCT00776698</DOCNO>
	<brief_summary>This single arm study evaluate feasibility treatment 2 dose level Avastin combination concurrent thoracic radiation chemotherapy patient locally advance unresectable non-squamous non-small cell lung cancer . Two cohort patient receive 3 cycle Avastin treatment ( 7.5mg/kg 15mg/kg iv every 3 week , respectively ) , concurrently thoracic radiation chemotherapy ( cisplatin etoposide ) . Once preferred dose establish , dose apply 3rd cohort , receive maintenance treatment Avastin single agent 6 additional cycle . The anticipated time study treatment &lt; 3 month cohorts 1 2 , 3-12 month cohort 3 , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Thoracic Radiation Chemotherapy Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>adult patient , &gt; = 18 year age ; nonsquamous nonsmall cell lung cancer , locally advanced unresectable ; ECOG performance status 0 1 ; prior thoracic head neck radiation ; prior surgical resection current lung cancer . malignancy nonsmall cell lung cancer within 2 year prior inclusion , except basal cell cancer skin , squamous cancer skin , cancer situ cervix ; prior systemic therapy nonsmall cell lung cancer ; clinically significant cardiovascular disease ; history &gt; = grade 2 hemoptysis ; current recent use aspirin ( &gt; 325mg/day ) full dose anticoagulant thrombolytic agent therapeutic purpose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>